Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527726 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4532522 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4527505 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4527720 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4527501 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4527507 | 1.00 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4523685 | 0.93 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL4530944 | 0.93 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL4523680 | 0.93 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL4537342 | 0.93 | REN (0.49) | RENCYP3A4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885CYP3A4 534/4885SLC6A2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.